检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Alexander J Thompson,Kathy Jackson,Sara Bonanzinga,Sam A L Hall,Simon Hume,Gareth S Burns,Vijaya Sundararajan,Dilip Ratnam,Miriam T Levy,John Lubel,Amanda J Nicoll,Simone I Strasser,William Sievert,Paul V Desmond,Meng C Ngu,Marie Sinclair,Christopher Meredith,Gail Matthews,Peter A Revill,Margaret Littlejohn,D Scott Bowden,Jesse A Canchola,Jason Torres,Philip Siew, Jasmin Lau,Benjamin La Brot,Alison Kuchta,Kumar Visvanathan

Hepatology communications（2023）

引用 0|浏览25
暂无评分
摘要
Serum HBV RNA may be a useful biomarker for guiding clinical decision-making before stopping nucleot(s)ide analog therapy. Baseline HBV RNA and HBsAg levels are associated with the risk of clinical relapse, hepatitis flare, and disease remission off-treatment.
更多
查看译文
关键词
baseline serum hbv rna,hepatitis flare,nucleoside analog therapy,hbeag-negative
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要